OPKO Health, Inc. OPK
Updated: 18 Jun 2026
No signal published yet
We already track OPKO Health and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow OPKO Health, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow OPKO Health free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 15, 2026, subsidiary OPKO Biologics presented preclinical data for its acromegaly candidate OPK8801001 at the ENDO 2026 conference. Earlier in June 2026, the company expanded its agreement with Nicoya Therapeutics, securing a 15% equity stake to support the commercialization of RAYALDEE in Greater China.
What Firelda Watch includes for OPKO Health, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow OPKO Health, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow OPKO Health free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more